Compare RBKB & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RBKB | CHRS |
|---|---|---|
| Founded | 1860 | 2010 |
| Country | United States | United States |
| Employees | 168 | N/A |
| Industry | Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.3M | 186.0M |
| IPO Year | 2018 | 2014 |
| Metric | RBKB | CHRS |
|---|---|---|
| Price | $16.15 | $1.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.51 |
| AVG Volume (30 Days) | 17.7K | ★ 1.9M |
| Earning Date | 04-27-2026 | 04-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 109.88 |
| EPS | 0.70 | ★ 1.77 |
| Revenue | ★ $3,002,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $79.63 |
| P/E Ratio | $22.87 | ★ $0.95 |
| Revenue Growth | ★ 4.24 | N/A |
| 52 Week Low | $9.31 | $0.72 |
| 52 Week High | $16.23 | $2.62 |
| Indicator | RBKB | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 77.16 | 43.47 |
| Support Level | $11.38 | $1.55 |
| Resistance Level | N/A | $1.75 |
| Average True Range (ATR) | 0.62 | 0.11 |
| MACD | 0.14 | -0.04 |
| Stochastic Oscillator | 95.86 | 13.71 |
Rhinebeck Bancorp Inc is the holding company for Rhinebeck Bank which provides a full range of banking and financial services to consumer and commercial customers. Financial services, including investment advisory and financial product sales, are offered through a division of the Bank doing business as Rhinebeck Asset Management (RAM). The Bank's primary business activity is accepting deposits from the general public and using those funds to originate indirect automobile loans (automobile loans referred by automobile dealerships), commercial real estate loans (which include multi-family real estate loans and commercial construction loans), commercial business loans and one-to four-family residential real estate loans, and to purchase investment securities.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.